[go: up one dir, main page]

NO20012961L - Trisykliske farnesylproteintransferase-inhibitorer - Google Patents

Trisykliske farnesylproteintransferase-inhibitorer

Info

Publication number
NO20012961L
NO20012961L NO20012961A NO20012961A NO20012961L NO 20012961 L NO20012961 L NO 20012961L NO 20012961 A NO20012961 A NO 20012961A NO 20012961 A NO20012961 A NO 20012961A NO 20012961 L NO20012961 L NO 20012961L
Authority
NO
Norway
Prior art keywords
group
protein transferase
farnesyl protein
stands
transferase inhibitors
Prior art date
Application number
NO20012961A
Other languages
English (en)
Other versions
NO20012961D0 (no
Inventor
Arthur G Taveras
Ronald J Doll
Alan Bruce Cooper
Johan A Ferreira
Timothy Guzi
Alan K Mallams
Dinanath F Rane
Viyyoor Moopil Girijavallabhan
Adriano Afonso
Cynthia J Aki
Jianping Chao
Carmen Alvarez
Joseph M Kelly
Tarik Lalwani
Jagdish A Desai
James J S Wang
Jay Weinstein
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20012961D0 publication Critical patent/NO20012961D0/no
Publication of NO20012961L publication Critical patent/NO20012961L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives forbindelser med. formel (1.0). hvori Rstår for en imidazolring,står for en karbamatgruppe, ureagruppe,. amidgruppe eller sulfonamidgruppe,står for H dersom alkylkjeden mellom amid-gruppen ogimidazolgruppen erubsti-tuert, eller Rstår for en substituent som arylalkyl, heteroarylalkyl eller sykloalkyl, og de gjenværende substitu-enter er som definert heri. Videre beskrives forbindelser hvorier H ogklkjeden mellom amigppogimidazolgruppen er ikke substituert. Videre beskrives en fremgangsmåte for behandling av cancer og en fremgangsmåte for inhibering av farnesylproteintrans-ferase ved anvendelse av de beskrevne forbindelser.
NO20012961A 1998-12-18 2001-06-15 Trisykliske farnesylproteintransferase-inhibitorer NO20012961L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21639898A 1998-12-18 1998-12-18
PCT/US1999/027939 WO2000037459A1 (en) 1998-12-18 1999-12-16 Tricyclic farnesyl protein transferase inhibitors

Publications (2)

Publication Number Publication Date
NO20012961D0 NO20012961D0 (no) 2001-06-15
NO20012961L true NO20012961L (no) 2001-08-16

Family

ID=22806914

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012961A NO20012961L (no) 1998-12-18 2001-06-15 Trisykliske farnesylproteintransferase-inhibitorer

Country Status (20)

Country Link
EP (1) EP1140902A1 (no)
JP (1) JP2002533336A (no)
KR (1) KR20010081116A (no)
CN (1) CN1326850C (no)
AR (1) AR021718A1 (no)
AU (1) AU776558B2 (no)
BR (1) BR9916314A (no)
CA (1) CA2354779A1 (no)
CO (1) CO5160350A1 (no)
CZ (1) CZ20011950A3 (no)
HU (1) HUP0202152A2 (no)
IL (1) IL143408A0 (no)
NO (1) NO20012961L (no)
NZ (1) NZ511878A (no)
PE (1) PE20001342A1 (no)
PL (1) PL348293A1 (no)
SK (1) SK7592001A3 (no)
TR (1) TR200101755T2 (no)
WO (1) WO2000037459A1 (no)
ZA (1) ZA200104233B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021718A1 (es) 1998-12-18 2002-07-31 Schering Corp Inhibidores de transferasa de proteina farnesilo.
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002080895A2 (en) * 2001-04-06 2002-10-17 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
MX2007007074A (es) 2004-12-13 2007-09-04 Schering Corp Inhibidores novedosos de proteina transferasa de farnesilo y su uso para tratar cancer.
CA2591123A1 (en) 2004-12-14 2006-06-22 Schering Corporation Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
CN106103424A (zh) * 2014-03-19 2016-11-09 维亚梅特制药公司 2‑(2,4‑二氟苯基)‑1,1‑二氟‑1‑(5‑经取代的吡啶‑2‑基)‑3‑(1h‑四唑‑1‑基)丙烷‑2‑醇和其制备方法
EP3119756B9 (en) 2014-03-19 2021-08-25 Dow AgroSciences LLC 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
CN1266433A (zh) * 1997-06-17 2000-09-13 先灵公司 用于抑制法呢基蛋白转移酶的苯并吡啶并环庚烷化合物
AR021718A1 (es) 1998-12-18 2002-07-31 Schering Corp Inhibidores de transferasa de proteina farnesilo.

Also Published As

Publication number Publication date
WO2000037459A1 (en) 2000-06-29
NZ511878A (en) 2003-10-31
HUP0202152A2 (en) 2002-10-28
KR20010081116A (ko) 2001-08-27
AR021718A1 (es) 2002-07-31
CO5160350A1 (es) 2002-05-30
SK7592001A3 (en) 2002-03-05
TR200101755T2 (tr) 2001-09-21
BR9916314A (pt) 2001-10-02
PL348293A1 (en) 2002-05-20
EP1140902A1 (en) 2001-10-10
ZA200104233B (en) 2002-08-22
IL143408A0 (en) 2002-04-21
AU776558B2 (en) 2004-09-16
CN1334811A (zh) 2002-02-06
PE20001342A1 (es) 2000-12-09
CA2354779A1 (en) 2000-06-29
NO20012961D0 (no) 2001-06-15
JP2002533336A (ja) 2002-10-08
CZ20011950A3 (cs) 2001-12-12
AU2030700A (en) 2000-07-12
CN1326850C (zh) 2007-07-18

Similar Documents

Publication Publication Date Title
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
DK1076663T3 (da) Funktionaliserede alkyl- og alkenylsidekædederivater af glycinamider som farnesyltransferaseinhibitorer
DE69314456D1 (de) Arylsulfonamido-substituierte Hydroxamsäure Derivate
CA2354774A1 (en) Farnesyl protein transferase inhibitors
DK0677039T3 (da) Cyclobutanderivater som squalen-syntetase- og protein-farnesyltransferaseinhibitorer
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
CA2318145A1 (en) Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
DK1054874T3 (da) Substituerede aminophenylisoxazolinderivater, der er anvendelige som antimokrobielle midler
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
NO963370L (no) Nye mercaptoacetylamido-1,3,4,5-tetrahydrobenzo[cÅazepin-3-on-disulfidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
NO964095L (no) Nye hydroksypyridinoner
NO20012961L (no) Trisykliske farnesylproteintransferase-inhibitorer
KR20050042829A (ko) 세포 유착 저해제
AU7949791A (en) Diaminotrifluoromethylpyridine derivatives, process for their production and phospholipase a2 inhibitor containing them
MXPA04004802A (es) Derivados del 1,2,4-triazol que contienen un grupo sulfamato como inhibidores de aromatasa.
BR0210746A (pt) Derivados de 6-'2-(fosfonometóxi)alcóxi-pirimidina tendo atividade antiviral
NO971142L (no) Bis-(2-halogenetyl)aminofenylsubstituerte distamycinderivater som antitumor- og antivirale midler
WO1998052917A3 (en) Guanidinylation reagents
DE69709774D1 (de) Substituierte benzocycloheptapyridine derivate verwendbar als farnesyl-protein transferase inhibitoren
DK0490816T3 (da) Fluorforbindelser som aromatase-inhibitorer.
EP0713877A4 (en) QINGHAOSU DERIVATIVES USED TO COMBAT AIDS
NO991235D0 (no) Forbindelser anvendelige for inhibering av farnesylproteintransferase
ATE312086T1 (de) Phenoxazinanaloge zur behandlung von amyloidose
ATE248831T1 (de) Benzo(5,6)cyclohepta(1,2b)pyridine derivate anwendbar als farnesyl protein transferase inhibitoren
ATE228359T1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application